{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:44:55Z","timestamp":1789771495643,"version":"4.0.1"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.cyto.2023.156227","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:08:26Z","timestamp":1684973306000},"page":"156227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Chronic Epstein-Barr virus infection: A potential junction between primary Sj\u00f6gren\u2019s syndrome and lymphoma"],"prefix":"10.1016","volume":"168","author":[{"given":"Lufei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincheng","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronglin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqi","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.cyto.2023.156227_b0005","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.122037","article-title":"Sj\u00f6gren syndrome","volume":"186","author":"Mavragani","year":"2014","journal-title":"Can. Med. Assoc. J."},{"issue":"5","key":"10.1016\/j.cyto.2023.156227_b0010","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/BOR.0000000000000096","article-title":"Advances in the understanding and treatment of systemic complications in Sj\u00f6gren\u2019s syndrome","volume":"26","author":"Brito-Zer\u00f3n","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.cyto.2023.156227_b0015","unstructured":"S. Retamozo et al., Systemic manifestations of primary Sj\u00f6gren\u2019s syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients, Clin. Exp. Rheumatol., 37, Suppl 118, no. 3, pp. 97\u2013106."},{"issue":"1","key":"10.1016\/j.cyto.2023.156227_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0b013e31824125e4","article-title":"Prognosis and outcome of non-Hodgkin lymphoma in primary Sj\u00f6gren syndrome","volume":"91","author":"Voulgarelis","year":"2012","journal-title":"Medicine"},{"key":"10.1016\/j.cyto.2023.156227_b0025","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keac205","article-title":"Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies","author":"Hern\u00e1ndez-Molina","year":"2022","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.cyto.2023.156227_b0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jbspin.2017.01.006","article-title":"EBV-induced lymphoproliferative disorders in rheumatic patients: A systematic review of the literature","volume":"85","author":"Berti","year":"2018","journal-title":"Joint Bone Spine"},{"issue":"5","key":"10.1016\/j.cyto.2023.156227_b0035","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00296-012-2504-3","article-title":"EBV reactivation serological profile in primary Sj\u00f6gren\u2019s syndrome: An underlying trigger of active articular involvement?","volume":"33","author":"Pasoto","year":"2013","journal-title":"Rheumatol. Int."},{"issue":"8","key":"10.1016\/j.cyto.2023.156227_b0040","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/art.1780310812","article-title":"Possible involvement of Epstein-Barr virus in polyclonal B cell activation in Sj\u00f6gren\u2019s syndrome","volume":"31","author":"Yamaoka","year":"1988","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.cyto.2023.156227_b0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-83550-0","article-title":"Association between EBV serological patterns and lymphocytic profile of SjS patients support a virally triggered autoimmune epithelitis","volume":"11","author":"Barcelos","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2023.156227_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.590444","article-title":"Serological Evidence for the Association Between Epstein-Barr Virus Infection and Sj\u00f6gren\u2019s Syndrome","volume":"11","author":"Xuan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2023.156227_b0055","doi-asserted-by":"crossref","unstructured":"J.P. Dugan, C.B. Coleman, and B. Haverkos, Opportunities to Target the Life Cycle of Epstein-Barr Virus (EBV) in EBV-Associated Lymphoproliferative Disorders, Front. Oncol., vol. 9 (2019) p. 127, http:\/\/doi.org\/10.3389\/fonc.2019.00127.","DOI":"10.3389\/fonc.2019.00127"},{"issue":"2","key":"10.1016\/j.cyto.2023.156227_b0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00281-020-00792-2","article-title":"Epigenetic lifestyle of Epstein-Barr virus","volume":"42","author":"Buschle","year":"2020","journal-title":"Semin. Immunopathol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156227_b0065","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1128\/CMR.00044-10","article-title":"Progress and problems in understanding and managing primary epstein-barr virus infections","volume":"24","author":"Odumade","year":"2011","journal-title":"Clin. Microbiol. Rev."},{"issue":"1","key":"10.1016\/j.cyto.2023.156227_b0070","first-page":"49","article-title":"Epstein-Barr virus and the lacrimal gland pathology of Sj\u00f6gren\u2019s syndrome","volume":"143","author":"Pflugfelder","year":"1993","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156227_b0075","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/imr.12791","article-title":"Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases","volume":"291","author":"Latour","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cyto.2023.156227_b0080","doi-asserted-by":"crossref","unstructured":"J.M. Middeldorp, Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease, (2015), pp. 289\u2013323. http:\/\/doi.org\/10.1007\/978-3-319-22834-1_10.","DOI":"10.1007\/978-3-319-22834-1_10"},{"issue":"2","key":"10.1016\/j.cyto.2023.156227_b0085","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/j.seminoncol.2014.12.030","article-title":"Epstein-Barr Virus-Associated Lymphomas","volume":"42","author":"Grywalska","year":"2015","journal-title":"Semin. Oncol."},{"issue":"12","key":"10.1016\/j.cyto.2023.156227_b0090","doi-asserted-by":"crossref","first-page":"7355","DOI":"10.1128\/JVI.79.12.7355-7362.2005","article-title":"Epstein-Barr virus LMP2A alters in vivo and in vitro models of B-cell anergy, but not deletion, in response to autoantigen","volume":"79","author":"Swanson-Mungerson","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.cyto.2023.156227_b0095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","article-title":"Epstein-Barr Virus and Cancer","volume":"14","author":"Farrell","year":"2019","journal-title":"Annu. Rev. Pathol."},{"issue":"10","key":"10.1016\/j.cyto.2023.156227_b0100","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4161\/cbt.10.10.13923","article-title":"Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention","volume":"10","author":"Saha","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.cyto.2023.156227_b0105","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.molimm.2018.12.010","article-title":"Evaluation of Epstein-Barr virus-specific antibodies in Cypriot multiple sclerosis patients","volume":"105","author":"Deeba","year":"2019","journal-title":"Mol. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2023.156227_b0110","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/jmv.24904","article-title":"Association of clinical and serological parameters of systemic lupus erythematosus patients with Epstein-Barr virus antibody profile","volume":"90","author":"Chougule","year":"2018","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.cyto.2023.156227_b0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/antib8020035","article-title":"\u2018EBNA1 IgM-Based Discrimination Between Rheumatoid Arthritis Patients, Systemic Lupus Erythematosus Patients and Healthy Controls","volume":"8","author":"Trier","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.cyto.2023.156227_b0120","doi-asserted-by":"crossref","unstructured":"K. Bjornevik et al., MULTIPLE SCLEROSIS Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis, 2022. [Online]. Available: https:\/\/www.science.org.","DOI":"10.1126\/science.abj8222"},{"issue":"7900","key":"10.1016\/j.cyto.2023.156227_b0125","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cyto.2023.156227_b0130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nm1167","article-title":"Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry","volume":"11","author":"McClain","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.cyto.2023.156227_b0135","doi-asserted-by":"crossref","unstructured":"A. H. Draborg, N. Sandhu, N. Larsen, J. Lisander Larsen, S. Jacobsen, and G. Houen, Impaired Cytokine Responses to Epstein-Barr Virus Antigens in Systemic Lupus Erythematosus Patients, J. Immunol. Res., vol. 2016, pp. 1\u201316, 2016, http:\/\/doi.org\/10.1155\/2016\/6473204.","DOI":"10.1155\/2016\/6473204"},{"issue":"MAY","key":"10.1016\/j.cyto.2023.156227_b0140","article-title":"Discrepancy of serological and molecular patterns of circulating Epstein-Barr virus reactivation in primary Sj\u00f6gren\u2019s syndrome","volume":"10","author":"Sanosyan","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2023.156227_b0145","doi-asserted-by":"crossref","unstructured":"N. Miyasaka, K. Yamaoka, M. Tateishi, K. Nishioka, and K. Yamamoto, \u2018Possible Involvement of Epstein-Barr Virus (EBV) in Polyclonal B-cell Activation in S jagren\u2019s Syndrome\u2019, 1989.","DOI":"10.1016\/0896-8411(89)90171-6"},{"issue":"6","key":"10.1016\/j.cyto.2023.156227_b0150","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1084\/jem.169.6.2191","article-title":"Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjogren\u2019s syndrome","volume":"169","author":"Saito","year":"1989","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cyto.2023.156227_b0155","doi-asserted-by":"crossref","unstructured":"G. Nocturne, E. Pontarini, M. Bombardieri, X. Mariette, Lymphomas complicating primary Sj\u00f6gren\u2019s syndrome: from autoimmunity to lymphoma, Rheumatology (Oxford), Mar. 2019, http:\/\/doi.org\/10.1093\/rheumatology\/kez052.","DOI":"10.1093\/rheumatology\/kez052"},{"key":"10.1016\/j.cyto.2023.156227_b0160","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.coviro.2015.03.014","article-title":"Animal models of Epstein Barr virus infection","volume":"13","author":"Gujer","year":"2015","journal-title":"Curr. Opin. Virol."},{"issue":"6","key":"10.1016\/j.cyto.2023.156227_b0165","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.celrep.2013.11.041","article-title":"Human Natural Killer Cells Prevent Infectious Mononucleosis Features by Targeting Lytic Epstein-Barr Virus Infection","volume":"5","author":"Chijioke","year":"2013","journal-title":"Cell Rep."},{"issue":"10","key":"10.1016\/j.cyto.2023.156227_b0170","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1084\/jem.20081761","article-title":"Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from toll-like receptor 3","volume":"206","author":"Iwakiri","year":"2009","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.cyto.2023.156227_b0175","doi-asserted-by":"crossref","first-page":"e539","DOI":"10.1002\/ctm2.539","article-title":"Clinical and molecular features of Epstein-Barr virus-positive diffuse large B-cell lymphoma: Results in a multi-center trial","volume":"11","author":"Zhao","year":"2021","journal-title":"Clin. Transl. Med."},{"issue":"6","key":"10.1016\/j.cyto.2023.156227_b0180","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/emboj\/17.6.1700","article-title":"Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor","volume":"17","author":"Kilger","year":"1998","journal-title":"EMBO J."},{"issue":"3","key":"10.1016\/j.cyto.2023.156227_b0185","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1074-7613(00)80623-8","article-title":"Epstein-Barr Virus LMP2A Drives B Cell Development and Survival in the Absence of Normal B Cell Receptor Signals","volume":"9","author":"Caldwell","year":"1998","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.cyto.2023.156227_b0190","doi-asserted-by":"crossref","first-page":"608","DOI":"10.4049\/jimmunol.1203440","article-title":"Different stages of primary Sjogren\u2019s syndrome involving lymphotoxin and type 1 IFN","volume":"191","author":"Shen","year":"2013","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2023.156227_b0195","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/BOR.0b013e32835c7e32","article-title":"The interferon signature in autoimmune diseases","volume":"25","author":"R\u00f6nnblom","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"issue":"9","key":"10.1016\/j.cyto.2023.156227_b0200","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.4049\/jimmunol.166.9.5801","article-title":"Possible involvement of EBV-mediated alpha-fodrin cleavage for organ-specific autoantigen in Sjogren\u2019s syndrome","volume":"166","author":"Inoue","year":"2001","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2023.156227_b0205","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jaut.2005.09.021","article-title":"Identification of tear lipocalin as a novel autoantigen target in Sj\u00f6gren\u2019s syndrome","volume":"25","author":"Navone","year":"2005","journal-title":"J. Autoimmun."},{"issue":"3","key":"10.1016\/j.cyto.2023.156227_b0210","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0092-8674(95)90489-1","article-title":"The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family","volume":"80","author":"Mosialos","year":"1995","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.cyto.2023.156227_b0215","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.4049\/jimmunol.163.12.6659","article-title":"Activation and targeting of immunoglobulin switch recombination by activities induced by EBV infection","volume":"163","author":"Li","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2023.156227_b0220","doi-asserted-by":"crossref","unstructured":"E. Corsiero, A. Nerviani, M. Bombardieri, and C. Pitzalis, Ectopic lymphoid structures: Powerhouse of autoimmunity, Front. Immunol., vol. 7, no. OCT. Frontiers Media S.A., Oct. 17, 2016. http:\/\/doi.org\/10.3389\/fimmu.2016.00430.","DOI":"10.3389\/fimmu.2016.00430"},{"issue":"8","key":"10.1016\/j.cyto.2023.156227_b0225","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.immuni.2022.06.020","article-title":"Interleukin-21, acting beyond the immunological synapse, independently controls T follicular helper and germinal center B cells","volume":"55","author":"Quast","year":"2022","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.cyto.2023.156227_b0230","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.4049\/jimmunol.180.7.5130","article-title":"CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren\u2019s syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization","volume":"180","author":"Barone","year":"2008","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.cyto.2023.156227_b0235","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.it.2012.04.006","article-title":"Tertiary lymphoid organs in infection and autoimmunity","volume":"33","author":"Neyt","year":"2012","journal-title":"Trends Immunol."},{"issue":"1\u20132","key":"10.1016\/j.cyto.2023.156227_b0240","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.imlet.2012.04.013","article-title":"Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases","volume":"145","author":"Corsiero","year":"2012","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.cyto.2023.156227_b0245","doi-asserted-by":"crossref","unstructured":"M. Bombardieri, M. Lewis, and C. Pitzalis, Ectopic lymphoid neogenesis in rheumatic autoimmune diseases, Nat. Rev. Rheumatol., vol. 13, no. 3. Nature Publishing Group, pp. 141\u2013154, Mar. 01, 2017. http:\/\/doi.org\/10.1038\/nrrheum.2016.217.","DOI":"10.1038\/nrrheum.2016.217"},{"issue":"9","key":"10.1016\/j.cyto.2023.156227_b0250","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1002\/art.38726","article-title":"Implication of Epstein-Barr virus infection in disease-specific autoreactive B cell activation in ectopic lymphoid structures of Sj\u00f6gren\u2019s syndrome","volume":"66","author":"Croia","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"10.1016\/j.cyto.2023.156227_b0255","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/ard.2010.144782","article-title":"Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sj\u00f6gren\u2019s syndrome","volume":"70","author":"Theander","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.cyto.2023.156227_b0260","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.bbi.2010.04.013","article-title":"Glucocorticoids activate Epstein Barr virus lytic replication through the upregulation of immediate early BZLF1 gene expression","volume":"24","author":"Yang","year":"2010","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.cyto.2023.156227_b0265","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/0014-5793(91)80767-W","article-title":"Activation of Epstein-Barr virus promoters by a growth-factor and a glucocorticoid","volume":"284","author":"Schuster","year":"1991","journal-title":"FEBS Lett."},{"issue":"4","key":"10.1016\/j.cyto.2023.156227_b0270","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/1756-185X.13800","article-title":"Characteristics of diffuse large B-cell lymphoma in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"23","author":"Gorodetskiy","year":"2020","journal-title":"Int. J. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.cyto.2023.156227_b0275","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1038\/emm.2014.109","article-title":"EBV and human cancer","volume":"47","author":"Ko","year":"2015","journal-title":"Exp. Mol. Med."},{"issue":"2","key":"10.1016\/j.cyto.2023.156227_b0280","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00277-018-3515-2","article-title":"Autoimmune disease-associated non-Hodgkin\u2019s lymphoma-a large retrospective study from China","volume":"98","author":"Hu","year":"2019","journal-title":"Ann. Hematol."},{"issue":"8","key":"10.1016\/j.cyto.2023.156227_b0285","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1177\/0961203319857132","article-title":"Prognostic markers of lymphoma development in primary Sj\u00f6gren syndrome","volume":"28","author":"Retamozo","year":"2019","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.cyto.2023.156227_b0290","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.autrev.2018.08.007","article-title":"Lymphomagenesis in Sj\u00f6gren\u2019s syndrome: Predictive biomarkers towards precision medicine","volume":"18","author":"Goules","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cyto.2023.156227_b0295","doi-asserted-by":"crossref","unstructured":"A.V. Goules, A.G. Tzioufas, Lymphomagenesis in Sj\u00f6gren\u2019s syndrome: Predictive biomarkers towards precision medicine, Autoimmun. Rev, vol. 18, no. 2, pp. 137\u2013143, Feb. 2019, http:\/\/doi.org\/10.1016\/j.autrev.2018.08.007.","DOI":"10.1016\/j.autrev.2018.08.007"},{"issue":"2","key":"10.1016\/j.cyto.2023.156227_b0300","doi-asserted-by":"crossref","first-page":"e0116189","DOI":"10.1371\/journal.pone.0116189","article-title":"Predicting the outcome of Sjogren\u2019s syndrome-associated non-hodgkin\u2019s lymphoma patients","volume":"10","author":"Papageorgiou","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cyto.2023.156227_b0305","doi-asserted-by":"crossref","unstructured":"M. Voulgarelis, P.D. Ziakas, A. Papageorgiou, E. Baimpa, A. G. Tzioufas, and H.M. Moutsopoulos, Prognosis and outcome of non-Hodgkin lymphoma in primary Sj\u00f6gren syndrome, Medicine, vol. 91, no. 1, pp. 1\u20139, Jan. 2012, http:\/\/doi.org\/10.1097\/MD.0b013e31824125e4.","DOI":"10.1097\/MD.0b013e31824125e4"},{"key":"10.1016\/j.cyto.2023.156227_b0310","unstructured":"M. Fabris et al., High prevalence of Chlamydophila psittaci subclinical infection in Italian patients with Sj\u00f6gren\u2019s syndrome and parotid gland marginal zone B-cell lymphoma of MALT-type, Clin. Exp. Rheumatol., vol. 32, no. 1, pp. 61\u20135."},{"key":"10.1016\/j.cyto.2023.156227_b0315","doi-asserted-by":"crossref","unstructured":"Q. Cai, L. J. Medeiros, X. Xu, and K. H. Young, \u2018MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management.\u2019, Oncotarget, vol. 6, no. 36, pp. 38591\u2013616, Nov. 2015, doi: 10.18632\/oncotarget.5774.","DOI":"10.18632\/oncotarget.5774"},{"key":"10.1016\/j.cyto.2023.156227_b0320","unstructured":"F.N. Skopouli, E.E. Kousvelari, P. Mertz, E.S. Jaffe, P.C. Fox, and H.M. Moutsopoulos, c-myc mRNA expression in minor salivary glands of patients with Sj\u00f6gren\u2019s syndrome, J. Rheumatol., vol. 19, no. 5, pp. 693\u20139, May 1992."},{"issue":"25","key":"10.1016\/j.cyto.2023.156227_b0325","doi-asserted-by":"crossref","first-page":"14421","DOI":"10.1073\/pnas.1921139117","article-title":"Functional interplay of Epstein-Barr virus oncoproteins in a mouse model of B cell lymphomagenesis","volume":"117","author":"Sommermann","year":"2020","journal-title":"PNAS"},{"key":"10.1016\/j.cyto.2023.156227_b0330","doi-asserted-by":"crossref","unstructured":"G. Nocturne et al., Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren\u2019s syndrome, Blood, vol. 122, no. 25, pp. 4068\u201376, Dec. 2013, http:\/\/doi.org\/10.1182\/blood-2013-05-503383.","DOI":"10.1182\/blood-2013-05-503383"},{"key":"10.1016\/j.cyto.2023.156227_b0335","doi-asserted-by":"crossref","unstructured":"E. Chanudet et al., TNFAIP3 abnormalities in MALT lymphoma with autoimmunity, Br. J. Haematol., vol. 154, no. 4, pp. 535\u20139, Aug. 2011, http:\/\/doi.org\/10.1111\/j.1365-2141.2011.08624.x.","DOI":"10.1111\/j.1365-2141.2011.08624.x"},{"issue":"2","key":"10.1016\/j.cyto.2023.156227_b0340","doi-asserted-by":"crossref","first-page":"e56741","DOI":"10.1371\/journal.pone.0056741","article-title":"A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders\/lymphomas","volume":"8","author":"Ando","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.cyto.2023.156227_b0345","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10238-020-00637-0","article-title":"Expression of BAFF and BAFF receptors in primary Sj\u00f6gren\u2019s syndrome patients with ectopic germinal center-like structures","volume":"20","author":"Carrillo-Ballesteros","year":"2020","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.cyto.2023.156227_b0350","doi-asserted-by":"crossref","unstructured":"A. Papageorgiou et al., A BAFF receptor His159Tyr mutation in Sj\u00f6gren\u2019s syndrome-related lymphoproliferation, Arthritis Rheumatol., vol. 67, no. 10, pp. 2732\u201341, Oct. 2015, http:\/\/doi.org\/10.1002\/art.39231.","DOI":"10.1002\/art.39231"},{"key":"10.1016\/j.cyto.2023.156227_b0355","doi-asserted-by":"crossref","unstructured":"B. He, N. Raab-Traub, P. Casali, and A. Cerutti, EBV-encoded latent membrane protein 1 cooperates with BAFF\/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching, J. Immunol., vol. 171, no. 10, pp. 5215\u201324, Nov. 2003, http:\/\/doi.org\/10.4049\/jimmunol.171.10.5215.","DOI":"10.4049\/jimmunol.171.10.5215"},{"key":"10.1016\/j.cyto.2023.156227_b0360","doi-asserted-by":"crossref","unstructured":"N. Gestermann et al., STAT4 is a confirmed genetic risk factor for Sj\u00f6gren\u2019s syndrome and could be involved in type 1 interferon pathway signaling, Genes Immun., vol. 11, no. 5, pp. 432\u20138, Jul. 2010, http:\/\/doi.org\/10.1038\/gene.2010.29.","DOI":"10.1038\/gene.2010.29"},{"key":"10.1016\/j.cyto.2023.156227_b0365","doi-asserted-by":"crossref","unstructured":"G. Nordmark et al., Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sj\u00f6gren\u2019s syndrome, Genes Immun., vol. 10, no. 1, pp. 68\u201376, Jan. 2009, http:\/\/doi.org\/10.1038\/gene.2008.94.","DOI":"10.1038\/gene.2008.94"},{"issue":"7","key":"10.1016\/j.cyto.2023.156227_b0370","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/PAS.0b013e3182515fb5","article-title":"Microscopic diffuse large B-cell lymphoma (DLBCL) occurring in pseudocysts: do these tumors belong to the category of DLBCL associated with chronic inflammation?","volume":"36","author":"Boroumand","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"issue":"6","key":"10.1016\/j.cyto.2023.156227_b0375","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/2326-6066.CIR-18-0698","article-title":"IL1R8 Deficiency Drives Autoimmunity-Associated Lymphoma Development","volume":"7","author":"Riva","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.cyto.2023.156227_b0380","doi-asserted-by":"crossref","unstructured":"S.J. Bowman, Primary Sj\u00f6gren\u2019s syndrome, Lupus, vol. 27, no. 1_suppl, pp. 32\u201335, Oct. 2018, http:\/\/doi.org\/10.1177\/0961203318801673.","DOI":"10.1177\/0961203318801673"},{"key":"10.1016\/j.cyto.2023.156227_b0385","doi-asserted-by":"crossref","unstructured":"C.P. Mavragani, T.B. Niewold, N.M. Moutsopoulos, S. R. Pillemer, S.M. Wahl, and M.K. Crow, Augmented interferon-alpha pathway activation in patients with Sj\u00f6gren\u2019s syndrome treated with etanercept, Arthritis Rheum., vol. 56, no. 12, pp. 3995\u20134004, Dec. 2007, http:\/\/doi.org\/10.1002\/art.23062.","DOI":"10.1002\/art.23062"},{"key":"10.1016\/j.cyto.2023.156227_b0390","doi-asserted-by":"crossref","unstructured":"A. Nezos et al., Type I and II interferon signatures in Sjogren\u2019s syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren\u2019s related lymphomagenesis, J. Autoimmun., vol. 63, pp. 47\u201358, Sep. 2015, http:\/\/doi.org\/10.1016\/j.jaut.2015.07.002.","DOI":"10.1016\/j.jaut.2015.07.002"},{"key":"10.1016\/j.cyto.2023.156227_b0395","doi-asserted-by":"crossref","first-page":"154781","DOI":"10.1016\/j.cyto.2019.154781","article-title":"TREX1 variants in Sjogren\u2019s syndrome related lymphomagenesis","volume":"132","author":"Nezos","year":"2020","journal-title":"Cytokine"},{"issue":"11","key":"10.1016\/j.cyto.2023.156227_b0400","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1038\/sj.leu.2403130","article-title":"Autocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells: induction via NF-\u03baB activation mediated by EBV-derived latent membrane protein 1","volume":"17","author":"Thompson","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.cyto.2023.156227_b0405","doi-asserted-by":"crossref","unstructured":"J.S. Pagano and A.K. Datta, Perspectives on interactions of acyclovir with Epstein-Barr and other herpes viruses, Am. J. Med., vol. 73, no. 1A, pp. 18\u201326, Jul. 1982, http:\/\/doi.org\/10.1016\/0002-9343(82)90057-2.","DOI":"10.1016\/0002-9343(82)90057-2"},{"key":"10.1016\/j.cyto.2023.156227_b0410","doi-asserted-by":"crossref","unstructured":"J.I. Cohen, Vaccine Development for Epstein-Barr Virus, 2018, pp. 477\u2013493. http:\/\/doi.org\/10.1007\/978-981-10-7230-7_22.","DOI":"10.1007\/978-981-10-7230-7_22"},{"issue":"5","key":"10.1016\/j.cyto.2023.156227_b0415","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","article-title":"Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells","volume":"50","author":"Bu","year":"2019","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.cyto.2023.156227_b0420","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein-Barr Virus Vaccine in Healthy Young Adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cyto.2023.156227_b0425","doi-asserted-by":"crossref","unstructured":"A. Bilger et al., Leflunomide\/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication, Oncotarget, vol. 8, no. 27, pp. 44266\u201344280, Jul. 2017, http:\/\/doi.org\/10.18632\/oncotarget.17863.","DOI":"10.18632\/oncotarget.17863"},{"issue":"8","key":"10.1016\/j.cyto.2023.156227_b0430","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/ard.2006.060905","article-title":"Safety and efficacy of leflunomide in primary Sjogren\u2019s syndrome: a phase II pilot study","volume":"66","author":"van Woerkom","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2023.156227_b0435","doi-asserted-by":"crossref","unstructured":"E. Doubrovina et al., Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation, Blood, vol. 119, no. 11, pp. 2644\u201356, Mar. 2012, http:\/\/doi.org\/10.1182\/blood-2011-08-371971.","DOI":"10.1182\/blood-2011-08-371971"},{"key":"10.1016\/j.cyto.2023.156227_b0440","doi-asserted-by":"crossref","unstructured":"M.P. Pender, P.A. Csurhes, J.M. Burrows, and S.R. Burrows, Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis, Clin. Transl. Immunol., vol. 6, no. 1, p. e126, Jan. 2017, http:\/\/doi.org\/10.1038\/cti.2016.87.","DOI":"10.1038\/cti.2016.87"},{"key":"10.1016\/j.cyto.2023.156227_b0445","doi-asserted-by":"crossref","unstructured":"S.S. Soldan and P.M. Lieberman, Epstein\u2013Barr virus and multiple sclerosis, Nat. Rev. Microbiol., vol. 21, no. 1. Nature Research, pp. 51\u201364, Jan. 01, 2023. http:\/\/doi.org\/10.1038\/s41579-022-00770-5.","DOI":"10.1038\/s41579-022-00770-5"},{"key":"10.1016\/j.cyto.2023.156227_b0450","doi-asserted-by":"crossref","unstructured":"N. Sutcliffe, M. Inanc, P. Speight, and D. Isenberg, Predictors of lymphoma development in primary Sj\u00f6gren\u2019s syndrome, Semin. Arthritis Rheum., vol. 28, no. 2, pp. 80\u20137, Oct. 1998, http:\/\/doi.org\/10.1016\/s0049-0172(98)80040-1.","DOI":"10.1016\/S0049-0172(98)80040-1"},{"key":"10.1016\/j.cyto.2023.156227_b0455","doi-asserted-by":"crossref","unstructured":"E. Theander, R. Manthorpe, and L.T.H. Jacobsson, Mortality and causes of death in primary Sj\u00f6gren\u2019s syndrome: a prospective cohort study, Arthritis Rheum., vol. 50, no. 4, pp. 1262\u20139, Apr. 2004, http:\/\/doi.org\/10.1002\/art.20176.","DOI":"10.1002\/art.20176"},{"issue":"21","key":"10.1016\/j.cyto.2023.156227_b0460","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.3390\/cancers13215534","article-title":"Clinical and Therapeutic Implications of Epstein-Barr Virus in HIV-Related Lymphomas","volume":"13","author":"Verdu-Bou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cyto.2023.156227_b0465","unstructured":"Epstein-Barr Virus-Induced Secondary High-Grade Transformation of Sj\u00f6 gren\u2019s Syndrome-Related Mucosa-Associated Lymphoid Tissue Lymphoma, 2013. [Online]. Available: www.jco.org."},{"key":"10.1016\/j.cyto.2023.156227_b0470","doi-asserted-by":"crossref","unstructured":"L.R. Teras et al., Epstein-Barr virus and risk of non-Hodgkin lymphoma in the cancer prevention study-II and a meta-analysis of serologic studies, Int. J. Cancer, vol. 136, no. 1, pp. 108\u201316, Jan. 2015, http:\/\/doi.org\/10.1002\/ijc.28971.","DOI":"10.1002\/ijc.28971"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466623001059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466623001059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:47:55Z","timestamp":1760910475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466623001059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":94,"alternative-id":["S1043466623001059"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156227","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Epstein-Barr virus infection: A potential junction between primary Sj\u00f6gren\u2019s syndrome and lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"156227"}}